Neurohumoral activation and progression of heart failure: Hypothetical and clinical considerations

Journal of Cardiovascular Pharmacology

Volumn 32, Issue SUPPL. 1, 1998, Pages

  Francis, Gary S ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adrenergic blockers; ET(A) inhibitors; Heart failure; Left ventricular remodeling

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; ENALAPRIL; ENDOTHELIN A RECEPTOR ANTAGONIST; LISINOPRIL; METOPROLOL;

BETA ADRENERGIC RECEPTOR BLOCKING; CONFERENCE PAPER; ENZYME INHIBITION; HEART FAILURE; HEART LEFT VENTRICLE MASS; HEART PERFORMANCE; HEART VENTRICLE REMODELING; HEMODYNAMICS; HORMONAL REGULATION; HORMONE RESPONSE; HUMAN; HYPOTHESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SURVIVAL;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DISEASE PROGRESSION; HEART FAILURE, CONGESTIVE; HUMANS; NEUROTRANSMITTER AGENTS; VENTRICULAR REMODELING;

EID: 0031688373     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800003-00004     Document Type: Conference Paper

References (71)

1. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J 1994;72:53-9.
2. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
3. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Circulation 1990;81:1161-72.
4. Braunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol 1991;68:1D-6D.
5. Gaudron P, Eilles C, Kugler I, Ertal G. Progressive left ventricular dysfunction and remodeling after myocardial infarction Circulation 1993;87:755-63.
6. Francis GS, Chu C. Post-infarction myocardial remodeling: why does it happen? Ear Heart J 1995;16:31-6.
7. Chien KR, Zhu H, Knowlton KU, et al. Transcriptional regulation during cardiac growth and development. Annu Rev Physiol 1993; 55:77-95.
8. Francis GS, Carlyle WC. Hypothetical pathways of cardiac myocyte hypertrophy: response to myocardial injury Eur Heart J 1993;14:49-56.
9. Katz AM. Cardiomyopathy of overload. N Engl J Med 1990;322: 100-10.
10. Katz AM. Scientific insights from clinical studies of converting enzyme inhibitors in the failing heart. Trends Cardiovasc Med 1995;5:37-44.
11. Weber KT, Pick R, Silver MA, et al. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation 1990;82: 1387-401.
12. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27: 341-8.
13. Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural and endocrine dependence. Circulation 1991;83:13-25
14. Francis GS, McDonald KM. Left ventricular hypertrophy: an initial response to myocardial injury. Am J Cardiol 1992;69:3G-9G.
15. Francis GS, McDonald KM, Cohn JN. Neurohumoral activation in preclinical heart failure. Circulation 1993;87(suppl IV):IV-90-6.
16. Konstam MA, Kronenberg MW, Rousseau MF, et al., for the SOLVD Investigators. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. Circulation 1993;88:2277-83.
17. Greenberg B, Quinones MA, Koilpillai C, et al., for the SOLVD Investigators. Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Circulation 1995;91:2573-81.
18. Doughty RN, Whalley GA, Gamble G, MacMahons, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060-6.
19. Franciosa JA, Wilen M, Ziesche S, Cohn JN. Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1983; 51:831-6.
20. Olivetti G, Capasso JM, Meggs LG, Sonnenblick EH, Anversa P. Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991;68:856-69.
21. Zellner JL, Spinale FG, Eble DM, Hewett KW, Crawford FA. Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. Circ Res 1991;69:590-600.
22. Spinale FG, Zellner JL, Tomita M, Crawford FA, Zile MR. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res 1990;69:1058-67.
23. Liu Z, Hilbelink DR, Crockett WB, Gerdes AM. Regional changes in hemodynamics and cardiac myocyte size in rats w ith aortocaval fistulas. Circ Res 1991;69:52-8.
24. Beltrami CA, Finato N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89:151-63.
25. Gerdes AM, Kellerman SE, Moore JA, et al. Structural remodeling of cardiac myocytes in patients with ischemic cardiomyopathy. Circulation 1992;86:426-30.
26. Cohn JN, Francis GS. Cardiac failure: a revised paradigm. J Card Fail 1995;1:261-6.
27. Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol 1995;27:849-56.
28. Jugdutt BI, Wamrnica JW. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Circulation 1988;78:906-19.
29. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989;83:1774-7.
30. McDonald KM, Mock J, D'Aloia A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995;91:2043-8.
31. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN. Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol 1994; 24:1762-8.
32. Simpson P, McGrath A, Savion S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines. Circ Res 1982;51:787-801.
33. 1-adrenergic receptor interaction. Circ Res 1985;56:884-94.
34. Zierhut W, Zimmer HG. Significance of myocardial α- and β-adrenoceptors in catecholamine-induced cardiac hypertrophy. Cin Res 1989;65:1417-25.
35. Dubus I, Samuel J-L, Marotte F, Delcayre C, Rappaport L. β-adrenergic agonists stimulate the synthesis of noncontractile but not contractile proteins in cultured myocytes isolated from adult rat heart. Circ Res 1990;66:867-74.
36. Long CS, Kariya K-I, Karns L, Simpson PC. Sympathetic activity: modulator of myocardial hypertrophy. J Cardiovasc Pharmacol 1991;17(Suppl 2):S20-4.
37. Clark WA, Rudnick SJ, LaPres JJ, Andersen LC, LaPointe MC. Regulation of hypertrophy and atrophy in cultured adult heart cells. Circ Res 1993;73:1163-76.
38. Yamazaki T, Komuro I, Zou Y, et al. Norepinephrine induces the raf-1 kinase/mitogen-activated protein kinase cascade through both α- and β-adrenoceptors. Circulation 1997;95:1260-8.
39. Roesler WJ, Vandenbark GR, Hanson RW. Cyclic AMP and the induction of eukaryotic gene transcription. J Biol Chem 1988;263: 9063-6.
40. Shabb JB, Corbin JD. Cyclic nucleotide-binding domains in proteins having diverse functions. J Biol Chem 1992;267:5723-6.
41. Walsh DA, Van Patten SM. Multiple pathway signal transduction by the cAMP-dependent protein kinase. FASEB J 1994;8:1227-36.
42. Müller FU, Boknik P, Horst A. et al. cAMP response element binding protein is expressed and phosphorylated in the human heart. Circulation 1995;92:2041-3.
43. Ferrari R, Bachetti T, Confortini R, et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995;92:1479-86.
44. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11.
45. 130 Signaling pathways: recent advances and implications for cardiovascular disease. Trends Cardiovasc Med 1996;6:109-15.
46. 130 in cardiac myocytes. Circulation 1996;94:2626-32.
47. Woller KC, Taga T, Saito M, et al. Cardiotrophin-I activates a distinct form of cardiac muscle cell hypertrophy. J Biol Chem 1996;271:9535-43.
48. Trinick J. Titin and nebulin: protein rulers in muscles? Trends Biol Sci 1994;19:405-9.
49. Labeit S, Kolmerer B. Titins: giant proteins in charge of muscle ultrastructure and elasticity. Science 1995;270:293-5.
50. Trombitas K, Jin J-P, Granzier H. The mechanically active domain of titin in cardiac muscle. Circ Res 1995;77:856-61.
51. Labeit S, Kolmerer B, Linke WA. The giant protein titin. Circ Res 1997:80:290-4.
52. Hiroe M, Hirata Y, Fujita N, et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991;68:1114-5.
53. Rodeheffer RJ, Lerman A, Heublein DM, Burnett JC. Increased plasma concentrations of endothelin in congestive heart failure in humans. Mayo Clin Proc 1992;67:719-24.
54. Lerman A, Kubo SH, Tschumperlin LK, Burnett JC. Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. J Am Coll Cardiol 1992;20:849-53.
55. Kiowski W, Sutsch G, Hunziker P, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995;346:732-6.
56. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996;384:353-5.
57. Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Circulation 1997;95:1918-29.
58. Luscher TF. The endothelium as a target and mediator of cardiovascular disease. Eur J Clin Invest 1993;23:670-85.
59. Yazaki Y, Yamazaki T. Reversing congestive heart failure with endothelin receptor antagonists. Circulation 1997;95:1752-4.
60. 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994;90:3034-46.
61. Williams JF, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure. J Am Coll Cardiol 1995;26:1376-98.
62. Australia-New Zealand Heart Failure Research Collaborative Group. Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 1995;92:212-8.
63. Australia/New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 1997;349:375-80.
64. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060-6.
65. Rahman MA, Hara K, Daly PA, Wigle ED, Floras JS. Reductions in muscle sympathetic nerve activity after long term metoprolol for dilated cardiomyopathy: preliminary observations. Br Heart J 1995;74:431-6.
66. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342: 1441-6.
67. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure. Circulation 1994;90:1765-73.
68. Packer M, Bristow MR, Cohn JN, et al., for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
69. Sackner-Bernstein JD, Mancini DM. Rationale for treatment of patients with chronic heart failure with adrenergic blockade. JAMA 1995;274:1462-7.
70. Zaremski DG, Nolan PE, Slack MK, Lui CY. Meta-analysis of the use of low-dose beta-adrenergic blocking therapy in idiopathic or ischemice dilated cardiomyopathy. Am J Cardiol 1996;77:1247-9.
71. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circulation 1996;94:2285-96.